Show simple item record

dc.contributor.authorMurray, I
dc.contributor.authorDu, Y
dc.date.accessioned2021-01-18T14:21:03Z
dc.date.issued2021-02
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2021, 33 (2), pp. 98 - 105
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4290
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2020.11.028
dc.description.abstractTreatments of bone metastases using radionuclides are now well established in oncology. It is also a field that continues to develop. This article reviews the evidence base that led to the approval of strontium-89 and samarium-153 ethylenediaminetetramethylene phophanate (EDTMP) for the palliation of pain from bone metastases, as well as the evidence for the use of radium-223 in metastatic castrate-resistant prostate cancer. Efforts to optimise treatments and improve response rates, either by safely increasing the radiation dose to bone metastases or by combining treatment with non-radiation-based therapies, are discussed. In addition, the development of both alpha- and beta-particle-emitting radiopharmaceuticals designed to target prostate-specific membrane antigen are reviewed.
dc.formatPrint
dc.format.extent98 - 105
dc.languageeng
dc.language.isoeng
dc.titleSystemic Radiotherapy of Bone Metastases With Radionuclides.
dc.typeJournal Article
dcterms.dateAccepted2020-11-30
rioxxterms.versionofrecord10.1016/j.clon.2020.11.028
rioxxterms.licenseref.startdate2021-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusAccepted
pubs.volume33
pubs.embargo.termsNot known
dc.contributor.icrauthorMurray,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record